Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvement

Sonya L. Heltshe; Steven M. Rowe; Michelle Skalland; Arthur Baines; Manu Jain

doi:10.1164/rccm.201710-2046LE

Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvement

Sonya L. Heltshe, Steven M. Rowe, Michelle Skalland, Arthur Baines, Manu Jain

Medicine, Pulmonary Division

Research output: Contribution to journal › Letter › peer-review

23 Scopus citations

Original language	English (US)
Pages (from-to)	1483-1486
Number of pages	4
Journal	American journal of respiratory and critical care medicine
Volume	197
Issue number	11
DOIs	https://doi.org/10.1164/rccm.201710-2046LE
State	Published - Jun 1 2018

Funding

Supported by the Spanish Respiratory Society, Associació Lleidatana de Respiratori, and ResMed. The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Supported by Cystic Fibrosis Foundation Therapeutics (GOAL11K1, GOAL13K0) and the NIH (DK072482, R35HL135816, DK089507, UL1TR001417, UL1TR002319).

ASJC Scopus subject areas

Critical Care and Intensive Care Medicine
Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1164/rccm.201710-2046LE

Cite this

@article{cdae27689c974bb2bb3f1df09cf8b2f8,

title = "Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvement",

author = "Heltshe, {Sonya L.} and Rowe, {Steven M.} and Michelle Skalland and Arthur Baines and Manu Jain",

note = "Funding Information: Supported by the Spanish Respiratory Society, Associaci{\'o} Lleidatana de Respiratori, and ResMed. The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding Information: Supported by Cystic Fibrosis Foundation Therapeutics (GOAL11K1, GOAL13K0) and the NIH (DK072482, R35HL135816, DK089507, UL1TR001417, UL1TR002319).",

year = "2018",

month = jun,

day = "1",

doi = "10.1164/rccm.201710-2046LE",

language = "English (US)",

volume = "197",

pages = "1483--1486",

journal = "American journal of respiratory and critical care medicine",

issn = "1073-449X",

publisher = "American Thoracic Society",

number = "11",

}

TY - JOUR

T1 - Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvement

AU - Heltshe, Sonya L.

AU - Rowe, Steven M.

AU - Skalland, Michelle

AU - Baines, Arthur

AU - Jain, Manu

N1 - Funding Information: Supported by the Spanish Respiratory Society, Associació Lleidatana de Respiratori, and ResMed. The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding Information: Supported by Cystic Fibrosis Foundation Therapeutics (GOAL11K1, GOAL13K0) and the NIH (DK072482, R35HL135816, DK089507, UL1TR001417, UL1TR002319).

PY - 2018/6/1

Y1 - 2018/6/1

UR - http://www.scopus.com/inward/record.url?scp=85048138339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048138339&partnerID=8YFLogxK

U2 - 10.1164/rccm.201710-2046LE

DO - 10.1164/rccm.201710-2046LE

M3 - Letter

C2 - 29256624

AN - SCOPUS:85048138339

SN - 1073-449X

VL - 197

SP - 1483

EP - 1486

JO - American journal of respiratory and critical care medicine

JF - American journal of respiratory and critical care medicine

IS - 11

ER -

Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvement

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this